Multigene Profiling of CTCs in MCRPC Identifies a Clinically Relevant Prognostic Signature

The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer-related genes. CTCs were isolated from the whole blood of mCRPC patients ( = 41) and multiplex qPCR was performed to evaluate expression of prostate cancer-related target genes ( = 78). A large fraction of patients (27/41, 66%) had detectable CTCs. Increased androgen receptor () expression (70% of samples) and evidence of Wnt signaling (67% of samples) were observed. The fusion was expressed in 41% of samples, and the aggressive prostate cancer-associated long noncoding RNA was upregulated in 70%. [HR 3.62, 95% confidence interval (CI), 1.63-8.05, = 0.002], (HR 5.56, 95% CI, 1.79-17.20, = 0.003), and (HR 3.86, 95% CI, 1.60-9.32, = 0.003) were independently predictive of overall survival (FDR < 10%) after adjusting for a panel of previously established prognostic variables in mCRPC (Halabi nomogram). A model including Halabi, , and expression, termed the miCTC score, outperformed the Halabi nomogram alone (AUC = 0.89 vs. AUC = 0.70). Understanding the molecular landscape of CTCs has utility in predicting clinical outcomes in patients with aggressive prostate cancer and provides an additional tool in the arsenal of precision-based therapeutic approaches in oncology. Analysis of CTC gene expression reveals a clinically prognostic "liquid biopsy" signature in patients with metastatic castrate-resistance prostate cancer. .